Skip to main content
Premium Trial:

Request an Annual Quote

FDA Declines Clearance of Nanosphere PMA for Plavix Metabolism Test

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere today said that it has received a not approvable letter from the US Food and Drug Administration for its Verigene Clopidogrel Metabolism Nucleic Acid Test.

Shares of Nanosphere dropped 24 percent to $1.69 in early Tuesday trade on the Nasdaq.

The Northbrook, Ill.-based molecular diagnostics firm had filed a premarket approval application with FDA for the test, which aims to evaluate whether a patient is successfully metabolizing the anti-platelet drug Plavix (clopidogrel). It received the not approvable letter on June 9, 2011, from the Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD) in the Center for Devices and Radiological Health.

Nanosphere said that it believes the deficiencies cited in the letter from the FDA are resolvable, and it believes that the test will ultimately gain clearance from the agency, "although there can be no assurance of such approval."

As a result of the delay, Nanosphere said it isn't likely to report revenues from the test in the US until 2012. The Plavix Metabolism test has the CE IVD Mark and is sold in certain European countries already. The firm expects to launch the test in additional European and Asian markets before the end of 2011.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.